Pelthos Therapeutics Files 8-K: Material Agreement, Debt, Equity Sales

Ticker: PTHS · Form: 8-K · Filed: 2025-11-07T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, debt, equity-sale

TL;DR

Pelthos Therapeutics inked a material deal, took on debt, and sold stock. Big moves happening.

AI Summary

Pelthos Therapeutics Inc. announced on November 7, 2025, that it entered into a material definitive agreement. The company also reported the creation of a direct financial obligation and unregistered sales of equity securities. The filing details events that occurred on November 6, 2025.

Why It Matters

This 8-K filing indicates significant corporate actions by Pelthos Therapeutics, including new financial obligations and equity transactions, which could impact its financial structure and shareholder value.

Risk Assessment

Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Pelthos Therapeutics?

The filing states that Pelthos Therapeutics Inc. entered into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.

What type of direct financial obligation was created by Pelthos Therapeutics?

The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement by Pelthos Therapeutics, but the specific details of the obligation are not elaborated in the provided text.

When did the events reported in this 8-K filing occur?

The earliest event reported in this 8-K filing occurred on November 6, 2025, and the report date is November 7, 2025.

Has Pelthos Therapeutics engaged in unregistered sales of equity securities?

Yes, the filing explicitly lists 'Unregistered Sales of Equity Securities' as an item of information, indicating such activity has occurred.

What is Pelthos Therapeutics Inc.'s Standard Industrial Classification (SIC) code?

Pelthos Therapeutics Inc.'s SIC code is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).

From the Filing

0001753926-25-001715.txt : 20251107 0001753926-25-001715.hdr.sgml : 20251107 20251107080154 ACCESSION NUMBER: 0001753926-25-001715 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 23 CONFORMED PERIOD OF REPORT: 20251107 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251107 DATE AS OF CHANGE: 20251107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pelthos Therapeutics Inc. CENTRAL INDEX KEY: 0001919246 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 863335449 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41964 FILM NUMBER: 251460580 BUSINESS ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 BUSINESS PHONE: 919-908-2422 MAIL ADDRESS: STREET 1: 4020 STIRRUP CREEK DRIVE STREET 2: SUITE 110 CITY: DURHAM STATE: NC ZIP: 27703 FORMER COMPANY: FORMER CONFORMED NAME: Channel Therapeutics Corp DATE OF NAME CHANGE: 20241118 FORMER COMPANY: FORMER CONFORMED NAME: Chromocell Therapeutics Corp DATE OF NAME CHANGE: 20220323 8-K 1 g084989_8k.htm FORM 8K false 0001919246 0001919246 2025-11-07 2025-11-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): November 7, 2025 (November 6, 2025)   Pelthos Therapeutics Inc. (Exact name of registrant as specified in its charter)   Nevada   001-41964   86-3335449 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   4020 Stirrup Creek Drive , Suite 110 Durham , NC   27703 (Address of registrant’s principal executive office)   (Zip code)   Registrant’s telephone number, including area code: (919) 908-2400   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   PTHS   The NYSE American LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01. Entry into a Material Definitive Agreement.   Convertible Note Financing (Private Placement)   On November 6, 2025, Pelthos Therapeutics Inc., a Nevada corporation

View on Read The Filing